CL2023003377A1 - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
CL2023003377A1
CL2023003377A1 CL2023003377A CL2023003377A CL2023003377A1 CL 2023003377 A1 CL2023003377 A1 CL 2023003377A1 CL 2023003377 A CL2023003377 A CL 2023003377A CL 2023003377 A CL2023003377 A CL 2023003377A CL 2023003377 A1 CL2023003377 A1 CL 2023003377A1
Authority
CL
Chile
Prior art keywords
antibody variants
canine antibody
canine
variants
relates
Prior art date
Application number
CL2023003377A
Other languages
English (en)
Inventor
Marie Bergeron Lisa
Luis CAMPOS Henry
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2023003377A1 publication Critical patent/CL2023003377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos caninos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo canino para mejorar su semivida y otras características.
CL2023003377A 2020-04-17 2023-11-13 Variantes de anticuerpos caninos CL2023003377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17

Publications (1)

Publication Number Publication Date
CL2023003377A1 true CL2023003377A1 (es) 2024-04-19

Family

ID=75888187

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002857A CL2022002857A1 (es) 2020-04-17 2022-10-17 Variantes de anticuerpos caninos
CL2023003377A CL2023003377A1 (es) 2020-04-17 2023-11-13 Variantes de anticuerpos caninos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022002857A CL2022002857A1 (es) 2020-04-17 2022-10-17 Variantes de anticuerpos caninos

Country Status (16)

Country Link
US (1) US20230242635A1 (es)
EP (1) EP4136106A1 (es)
JP (1) JP2023522029A (es)
KR (1) KR20230005156A (es)
CN (1) CN115996949A (es)
AU (1) AU2021256056A1 (es)
BR (1) BR112022020944A2 (es)
CA (1) CA3175921A1 (es)
CL (2) CL2022002857A1 (es)
CO (1) CO2022014695A2 (es)
EC (1) ECSP22080846A (es)
IL (1) IL297287A (es)
MX (1) MX2022012866A (es)
PE (1) PE20230108A1 (es)
TW (1) TW202204403A (es)
WO (1) WO2021212081A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP4149969A1 (en) 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
JP2023534636A (ja) 2020-07-10 2023-08-10 インベテックス インコーポレイテッド 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法
WO2022067233A2 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
WO2023250284A2 (en) * 2022-06-21 2023-12-28 Zoetis Services Llc Canine antibody mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
BRPI0515230A (pt) 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
CA3026050A1 (en) * 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
MX2021011335A (es) * 2019-03-20 2022-01-06 Kindred Biosciences Inc Antagonistas de ngf para uso medicinal.

Also Published As

Publication number Publication date
PE20230108A1 (es) 2023-01-25
US20230242635A1 (en) 2023-08-03
WO2021212081A1 (en) 2021-10-21
CA3175921A1 (en) 2021-10-21
CL2022002857A1 (es) 2023-06-02
BR112022020944A2 (pt) 2022-12-27
CN115996949A (zh) 2023-04-21
TW202204403A (zh) 2022-02-01
CO2022014695A2 (es) 2022-10-21
IL297287A (en) 2022-12-01
EP4136106A1 (en) 2023-02-22
AU2021256056A1 (en) 2022-10-20
JP2023522029A (ja) 2023-05-26
KR20230005156A (ko) 2023-01-09
MX2022012866A (es) 2022-11-08
ECSP22080846A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA202092847A1 (ru) Антитела к cd3 и их применение
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112018067458A2 (pt) anticorpos para tigit
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
ECSP23030271A (es) Variantes de anticuerpos caninos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
ECSP23057156A (es) Mutaciones en regiones constantes de anticuerpos caninos
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
ECSP23030307A (es) Variantes de anticuerpos felinos
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.
MX2023010648A (es) Novedosas combinaciones de anticuerpos y usos de estas.
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA201992186A1 (ru) Антитела к par2 и пути их применения